Highlights
- Optiscan and ACL enter a three-year collaboration to validate the InForm digital pathology platform.
- ACL’s laboratory network will support real-world testing and imaging data collection across tissue types.
- Partnership aims to streamline workflows and advance regulatory preparation for future submissions.
Optiscan Imaging Ltd (ASX:OIL) has entered into a three-year Strategic Collaboration Agreement with Australian Clinical Labs Ltd (ASX:ACL) to support the development, validation and deployment of the Company’s InForm digital pathology platform. The agreement is positioned to expand the use of real-time digital pathology within clinical environments in Australia and international markets.
Under the arrangement, Optiscan will gain access to ACL’s extensive pathology network to test the InForm device under active laboratory conditions. The collaboration is set to allow the Company to collect imaging data from a broad range of human tissues and associated pathologies, forming a databank intended for supporting pathologist training and system integration across anatomical pathology workflows.
Image Databank Development and Workflow Integration
A key component of the agreement involves the establishment of a comprehensive imaging databank. Data generated within ACL’s operating laboratories will be used to support training requirements for pathology professionals and assist in refining the InForm platform for routine application.
ACL, which operates 50 NATA-accredited laboratories, employs 85 RCPA-accredited pathologists, and manages 1,288 approved collection centres nationwide, will provide the operational environment required for real-world device evaluation. Its network of scientists, collectors and support personnel will enable Optiscan to assess workflow efficiency, imaging performance and device readiness across pathology and point-of-care settings.
Testing at ACL’s Flagship Western Australia Facility
As part of the initiative, Optiscan will conduct testing at ACL’s flagship anatomical pathology laboratory in Western Australia. The objective is to evaluate how the InForm device performs within high-volume pathology settings and ensure it aligns with the practical requirements of technicians, clinicians and laboratory processes.
Sector Implications and Operational Reach
The agreement marks a material operational step for Optiscan as the Company seeks to refine and position its digital pathology platform for broader industry use. With ACL among Australia's largest providers of hospital-based pathology services, the collaboration gives Optiscan an opportunity to generate clinical-grade insights and test end-to-end digital workflows that involve real-time microscopic imaging at the point of contact with tissue.
Share Performance of OIL
OIL was trading 11.36% high at AUD 0.122 per share as of 10 November 2025.






Please wait processing your request...